{"id":"abatacept-subcutaneous","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Infection (upper respiratory, urinary tract)"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL1201823","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Abatacept (CTLA4-Ig) acts as a selective co-stimulation modulator that interrupts the interaction between antigen-presenting cells and T cells. By binding to CD80 and CD86 ligands, it prevents the second signal required for full T-cell activation, thereby suppressing the proliferation and differentiation of autoreactive T cells. This mechanism makes it particularly effective in autoimmune conditions where T-cell-mediated inflammation drives disease pathology.","oneSentence":"Abatacept is a fusion protein that blocks T-cell co-stimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and reducing inflammatory responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:58:29.472Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Polyarticular juvenile idiopathic arthritis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Systemic lupus erythematosus"}]},"trialDetails":[{"nctId":"NCT07388563","phase":"PHASE1","title":"Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Lymphoma, T Cell, Peripheral, T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma","enrollment":20},{"nctId":"NCT07161999","phase":"PHASE2","title":"Study of COYA 302 for the Treatment of ALS","status":"RECRUITING","sponsor":"Coya Therapeutics","startDate":"2025-10-01","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":120},{"nctId":"NCT03929601","phase":"PHASE2","title":"Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2023-10-30","conditions":"Type 1 Diabetes Mellitus","enrollment":74},{"nctId":"NCT05782335","phase":"","title":"Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2022-11-01","conditions":"Rheumatoid Arthritis","enrollment":72},{"nctId":"NCT04474847","phase":"PHASE3","title":"Abatacept for the Treatment of Giant Cell Arteritis","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2021-03-29","conditions":"Giant Cell Arteritis","enrollment":78},{"nctId":"NCT04925375","phase":"PHASE2","title":"Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2021-07-14","conditions":"Interstitial Lung Disease, Common Variable Immunodeficiency","enrollment":38},{"nctId":"NCT05428488","phase":"PHASE3","title":"Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2022-11-28","conditions":"Rheumatoid Arthritis","enrollment":220},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT02758769","phase":"","title":"Long-Term Outcomes With Abatacept In Biologic Treatment-Naive Rheumatoid Arthritis Patients In Japanese Clinical Practice Settings","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-06-07","conditions":"Rheumatoid Arthritis","enrollment":303},{"nctId":"NCT06929039","phase":"PHASE1","title":"Open Label , Randomized, Three Arm Parallel Group Single Dose Comparative Pharmacokinetic , Safety and Immunogenicity Study in Healthy Subjects","status":"COMPLETED","sponsor":"Kashiv BioSciences, LLC","startDate":"2024-07-04","conditions":"Rheumatoid Arthritis (RA","enrollment":300},{"nctId":"NCT05975450","phase":"PHASE1","title":"Subcutaneous Abatacept in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Idelberto Badell","startDate":"2023-08-02","conditions":"Kidney Transplant Recipient","enrollment":14},{"nctId":"NCT06395038","phase":"PHASE1","title":"IL-2 Plus Abatacept in FTD","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2024-05-06","conditions":"Frontotemporal Degeneration","enrollment":10},{"nctId":"NCT03669367","phase":"PHASE4","title":"EFFECTS OF ABATACEPT on the Progression to Rheumatoid Arthritis(PALABA Study)","status":"COMPLETED","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2019-06-03","conditions":"Palindromic Rheumatism, Wrist","enrollment":70},{"nctId":"NCT04909801","phase":"PHASE3","title":"A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2021-09-15","conditions":"Rheumatoid Arthritis","enrollment":338},{"nctId":"NCT03215927","phase":"PHASE2","title":"Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease","status":"COMPLETED","sponsor":"Rohit Aggarwal, MD","startDate":"2018-01-01","conditions":"Myositis, Interstitial Lung Disease","enrollment":20},{"nctId":"NCT03737708","phase":"PHASE4","title":"A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2019-02-13","conditions":"Rheumatoid Arthritis (RA)","enrollment":21},{"nctId":"NCT03882008","phase":"PHASE4","title":"A Study to Evaluate Biomarkers to Predict Efficacy of Abatacept in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"University of Washington","startDate":"2019-05-23","conditions":"Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT02108860","phase":"PHASE3","title":"Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)","status":"COMPLETED","sponsor":"University of South Florida","startDate":"2015-04-25","conditions":"Granulomatosis With Polyangiitis (Wegener's), Granulomatosis With Polyangiitis, Wegener's Granulomatosis","enrollment":65},{"nctId":"NCT05981976","phase":"PHASE1","title":"A Study to Evaluate the Drug Levels of Abatacept Converted From Drug Substance by Two Different Processes in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2023-08-18","conditions":"Healthy Participants","enrollment":174},{"nctId":"NCT04118153","phase":"EARLY_PHASE1","title":"Early Markers of Disease and Response to Therapy","status":"COMPLETED","sponsor":"Sandra Lord, MD","startDate":"2021-03-05","conditions":"Type 1 Diabetes","enrollment":60},{"nctId":"NCT06307301","phase":"PHASE1","title":"Study in ALS With Abatacept & IL-2","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2021-10-28","conditions":"Amyotrophic Lateral Sclerosis","enrollment":5},{"nctId":"NCT06279494","phase":"PHASE1, PHASE2","title":"Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-03","conditions":"Acute Leukemia, Myelodysplastic Syndromes, Severe Aplastic Anemia","enrollment":6},{"nctId":"NCT06126042","phase":"PHASE1","title":"Comparative Pharmacokinetic Study of Three Abatacept Products in Male Normal Healthy Volunteers by the Subcutaneous Route","status":"UNKNOWN","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2023-10-03","conditions":"Rheumatoid Arthritis","enrollment":330},{"nctId":"NCT02971683","phase":"PHASE3","title":"Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-05-04","conditions":"Polymyositis, Dermatomyositis, Autoimmune Necrotizing Myopathy","enrollment":149},{"nctId":"NCT03227419","phase":"PHASE4","title":"Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders","status":"UNKNOWN","sponsor":"Lille Catholic University","startDate":"2018-01-22","conditions":"Arthritis, Rheumatoid","enrollment":224},{"nctId":"NCT03188081","phase":"","title":"A Study to Investigate the Effectiveness of an Education Support Program on Medication Adherence in Italian Real Life Rheumatoid Arthritis (RA) Patients Treated With Subcutaneous (SC) Abatacept","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-08-02","conditions":"Rheumatoid Arthritis","enrollment":171},{"nctId":"NCT03619876","phase":"PHASE4","title":"Effects of Abatacept on Myocarditis in Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Columbia University","startDate":"2019-07-10","conditions":"Rheumatoid Arthritis, Myocardial Inflammation","enrollment":11},{"nctId":"NCT04686929","phase":"PHASE1, PHASE2","title":"Abatacept s.c. for aGVHD Prevention in Haplo-HCT","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2021-06-01","conditions":"Abatacept, Acute-graft-versus-host Disease, Haplo-identical HCT","enrollment":29},{"nctId":"NCT02594735","phase":"PHASE4","title":"Abatacept in Juvenile Dermatomyositis","status":"COMPLETED","sponsor":"George Washington University","startDate":"2015-11","conditions":"Dermatomyositis","enrollment":10},{"nctId":"NCT03632187","phase":"PHASE3","title":"Abatacept in earLy Onset Polymyalgia Rheumatica: Study ALORS","status":"UNKNOWN","sponsor":"University Hospital, Brest","startDate":"2018-12-13","conditions":"Polymyalgia Rheumatica","enrollment":34},{"nctId":"NCT01860976","phase":"PHASE3","title":"Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-06-17","conditions":"Psoriatic Arthritis","enrollment":489},{"nctId":"NCT05303272","phase":"PHASE4","title":"A Study to Evaluate Efficacy and Safety of Abatacept in Participants of Pemphigus Vulgaris (PV)","status":"UNKNOWN","sponsor":"Tongji Hospital","startDate":"2021-02-01","conditions":"Pemphigus Vulgaris","enrollment":60},{"nctId":"NCT04203875","phase":"PHASE1","title":"Abatacept for Treatment of Recurrent or de Novo Autoimmune Hepatitis","status":"TERMINATED","sponsor":"Stuart Knechtle, M.D.","startDate":"2020-03-09","conditions":"Autoimmune Hepatitis","enrollment":1},{"nctId":"NCT03669861","phase":"PHASE2","title":"Safety and Efficacy of Abatacept in IgG4-Related Disease","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2018-11-13","conditions":"IgG4-related Disease","enrollment":10},{"nctId":"NCT02504268","phase":"PHASE3","title":"Effects of Abatacept in Patients With Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-09-03","conditions":"Rheumatoid Arthritis","enrollment":994},{"nctId":"NCT02429934","phase":"PHASE1, PHASE2","title":"Abatacept for SLE Arthritis (IM101-330)","status":"TERMINATED","sponsor":"University of California, Los Angeles","startDate":"2015-10","conditions":"Systemic Lupus Erythematosus Arthritis","enrollment":28},{"nctId":"NCT03411850","phase":"PHASE2","title":"Sjogrens Syndrome Measured by Ultrasound","status":"UNKNOWN","sponsor":"Arthritis & Rheumatism Associates, P.C.","startDate":"2016-05","conditions":"Sjogren's Syndrome","enrollment":20},{"nctId":"NCT02053727","phase":"NA","title":"Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2014-07","conditions":"Rheumatoid Arthritis, Chronic Hepatitis B","enrollment":""},{"nctId":"NCT02557100","phase":"PHASE4","title":"Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-11-19","conditions":"Rheumatoid Arthritis","enrollment":80},{"nctId":"NCT02915159","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens Syndrome","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-12-06","conditions":"Sjogrens Disease","enrollment":250},{"nctId":"NCT02161406","phase":"PHASE2","title":"A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis","status":"COMPLETED","sponsor":"Dinesh Khanna, MD, MS","startDate":"2014-09","conditions":"Diffuse Cutaneous Systemic Sclerosis","enrollment":88},{"nctId":"NCT03059888","phase":"EARLY_PHASE1","title":"Trial of Orencia in Patients With Myasthenia Gravis","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2017-04-12","conditions":"Myasthenia Gravis","enrollment":6},{"nctId":"NCT02067910","phase":"PHASE3","title":"Efficacy and Safety of Abatacept in Patients With Primary Sjögren's Syndrome","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2014-08","conditions":"Sjögren's Syndrome","enrollment":80},{"nctId":"NCT02018042","phase":"PHASE2","title":"An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata","status":"COMPLETED","sponsor":"Columbia University","startDate":"2013-09","conditions":"Alopecia Areata","enrollment":15},{"nctId":"NCT03274141","phase":"","title":"Comparing the Effectiveness of a Treat-to-target (T2T) Disease Management Strategy vs. Routine Care (RC) in Adult Patients With Moderate to Severe Rheumatoid Arthritis (RA) Treated With Subcutaneous Abatacept (Orencia - SC)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-10-31","conditions":"Rheumatoid Arthritis","enrollment":281},{"nctId":"NCT01999868","phase":"PHASE2","title":"Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-03-19","conditions":"Psoriasis","enrollment":108},{"nctId":"NCT02281058","phase":"PHASE1","title":"Open-label Pilot Study of Abatacept for the Treatment of Vitiligo","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2015-01","conditions":"Vitiligo","enrollment":10},{"nctId":"NCT03192969","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA)","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2017-07-15","conditions":"Giant Cell Arteritis","enrollment":""},{"nctId":"NCT02600455","phase":"","title":"Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-09","conditions":"Rheumatoid Arthritis","enrollment":505},{"nctId":"NCT02805010","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability Study of Single Dose of Abatacept 125mg Administered Subcutaneously","status":"UNKNOWN","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2016-10","conditions":"Rheumatoid Arthritis (RA)","enrollment":22},{"nctId":"NCT01295151","phase":"PHASE4","title":"SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.","status":"COMPLETED","sponsor":"Julia Brown","startDate":"2011-08","conditions":"Rheumatoid Arthritis","enrollment":122},{"nctId":"NCT00569803","phase":"PHASE1","title":"Subcutaneous Pharmacokinetics of Belatacept","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-12","conditions":"Transplantation","enrollment":153},{"nctId":"NCT02722694","phase":"PHASE3","title":"A Phase 3 Study of Abatacept in Chinese Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate","status":"UNKNOWN","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2016-08","conditions":"Rheumatoid Arthritis (RA)","enrollment":360},{"nctId":"NCT01717846","phase":"PHASE4","title":"Effect on Orencia (Abatacept) on the Apoptosis of T Cells, B Cells and APC Cells in Rheumatoid Arthritis","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2012-12","conditions":"Apoptotic DNA Damage, Rheumatoid Arthritis, T-cell Lymphocytosis","enrollment":""},{"nctId":"NCT02598466","phase":"","title":"Patient-Reported Efficacy of Subcutaneous (SC) Abatacept in Rheumatoid Arthritis (RA) - South Africa","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-07","conditions":"Rheumatoid Arthritis","enrollment":69},{"nctId":"NCT01142726","phase":"PHASE3","title":"Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-12","conditions":"Rheumatoid Arthritis","enrollment":511},{"nctId":"NCT02652273","phase":"PHASE4","title":"Inhibition of Co-Stimulation in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2016-01","conditions":"Arthritis, Rheumatoid","enrollment":25},{"nctId":"NCT00559585","phase":"PHASE3","title":"Methotrexate-Inadequate Response Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-01","conditions":"Rheumatoid Arthritis (RA)","enrollment":2492},{"nctId":"NCT01299961","phase":"PHASE3","title":"Ultrasound Scores as Indication of Response to Subcutaneous Abatacept in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2011-03","conditions":"Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT00533897","phase":"PHASE3","title":"Phase IIIB Subcutaneous Missed Dose Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-11","conditions":"Rheumatoid Arthritis","enrollment":270},{"nctId":"NCT00547521","phase":"PHASE3","title":"Phase IIIB Subcutaneous Abatacept Monotherapy Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-12","conditions":"Rheumatoid Arthritis (RA)","enrollment":119},{"nctId":"NCT00663702","phase":"PHASE3","title":"Phase IIIB Switching From Intravenous to Subcutaneous Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-05","conditions":"Arthritis, Rheumatoid","enrollment":123},{"nctId":"NCT01846975","phase":"PHASE4","title":"Introducing a Single IV Abatacept Treatment in RA Patients Currently Receiving Weekly SC Abatacept to Simulate a Holiday","status":"COMPLETED","sponsor":"Rüdiger B. Müller","startDate":"2013-05","conditions":"Rheumatoid Arthritis","enrollment":49},{"nctId":"NCT01917058","phase":"PHASE2","title":"A Clinical Trial to Evaluate the Efficacy of Abatacept in Moderate to Severe Alopecia Areata","status":"WITHDRAWN","sponsor":"Columbia University","startDate":"2013-08","conditions":"Alopecia Areata","enrollment":""},{"nctId":"NCT01333878","phase":"PHASE2, PHASE3","title":"Impact of Subcutaneous Abatacept in Rheumatoid Arthritis Assessing Inhibition of Structural Damage","status":"COMPLETED","sponsor":"Orrin M Troum, M.D. and Medical Associates","startDate":"2011-03","conditions":"Rheumatoid Arthritis","enrollment":12},{"nctId":"NCT00254293","phase":"PHASE1, PHASE2","title":"Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-01","conditions":"Rheumatoid Arthritis","enrollment":87},{"nctId":"NCT01001832","phase":"PHASE2, PHASE3","title":"Efficacy, Pharmacokinetics, Safety, and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japanese Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-12","conditions":"Rheumatoid Arthritis","enrollment":118},{"nctId":"NCT00929864","phase":"PHASE3","title":"Abatacept Versus Adalimumab Head-to-Head","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-10","conditions":"Rheumatoid Arthritis","enrollment":869},{"nctId":"NCT01173120","phase":"PHASE3","title":"Methotrexate - Inadequate Response Device Sub-Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-11","conditions":"Rheumatoid Arthritis (RA)","enrollment":62},{"nctId":"NCT00162279","phase":"PHASE2","title":"The Study of Abatacept in Combination With Etanercept","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2000-10","conditions":"Rheumatoid Arthritis","enrollment":141}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":165,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Abatacept subcutaneous","genericName":"Abatacept subcutaneous","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Abatacept is a fusion protein that blocks T-cell co-stimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and reducing inflammatory responses. Used for Rheumatoid arthritis, Polyarticular juvenile idiopathic arthritis, Psoriatic arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}